PRIVIA HEALTH GROUP INC (PRVA) Fundamental Analysis & Valuation
NASDAQ:PRVA • US74276R1023
Current stock price
21.68 USD
-0.05 (-0.23%)
At close:
21.68 USD
0 (0%)
After Hours:
This PRVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PRVA Profitability Analysis
1.1 Basic Checks
- In the past year PRVA was profitable.
- In the past year PRVA had a positive cash flow from operations.
- In multiple years PRVA reported negative net income over the last 5 years.
- PRVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- PRVA has a Return On Assets of 1.67%. This is comparable to the rest of the industry: PRVA outperforms 56.44% of its industry peers.
- PRVA has a Return On Equity (3.11%) which is comparable to the rest of the industry.
- The Return On Invested Capital of PRVA (2.75%) is comparable to the rest of the industry.
- PRVA had an Average Return On Invested Capital over the past 3 years of 2.17%. This is significantly below the industry average of 8.94%.
- The 3 year average ROIC (2.17%) for PRVA is below the current ROIC(2.75%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.67% | ||
| ROE | 3.11% | ||
| ROIC | 2.75% |
ROA(3y)1.75%
ROA(5y)-4.65%
ROE(3y)3.16%
ROE(5y)-7.26%
ROIC(3y)2.17%
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of PRVA (1.08%) is comparable to the rest of the industry.
- In the last couple of years the Profit Margin of PRVA has declined.
- Looking at the Operating Margin, with a value of 1.61%, PRVA is in line with its industry, outperforming 45.54% of the companies in the same industry.
- In the last couple of years the Operating Margin of PRVA has declined.
- Looking at the Gross Margin, with a value of 9.87%, PRVA is doing worse than 75.25% of the companies in the same industry.
- PRVA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.61% | ||
| PM (TTM) | 1.08% | ||
| GM | 9.87% |
OM growth 3YN/A
OM growth 5Y-12.3%
PM growth 3YN/A
PM growth 5Y-22.33%
GM growth 3Y-0.24%
GM growth 5Y-0.49%
2. PRVA Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PRVA is destroying value.
- Compared to 1 year ago, PRVA has more shares outstanding
- The number of shares outstanding for PRVA has been increased compared to 5 years ago.
- There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 4.32 indicates that PRVA is not in any danger for bankruptcy at the moment.
- PRVA has a Altman-Z score of 4.32. This is amongst the best in the industry. PRVA outperforms 81.19% of its industry peers.
- There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.32 |
ROIC/WACC0.31
WACC8.92%
2.3 Liquidity
- PRVA has a Current Ratio of 1.60. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.60, PRVA is in the better half of the industry, outperforming 63.37% of the companies in the same industry.
- A Quick Ratio of 1.60 indicates that PRVA should not have too much problems paying its short term obligations.
- PRVA has a Quick ratio of 1.60. This is in the better half of the industry: PRVA outperforms 65.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 |
3. PRVA Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 54.55% over the past year.
- The Earnings Per Share has been decreasing by -9.93% on average over the past years.
- PRVA shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.26%.
- PRVA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.04% yearly.
EPS 1Y (TTM)54.55%
EPS 3Y9.35%
EPS 5Y-9.93%
EPS Q2Q%133.33%
Revenue 1Y (TTM)22.26%
Revenue growth 3Y16.09%
Revenue growth 5Y21.04%
Sales Q2Q%-31.71%
3.2 Future
- The Earnings Per Share is expected to grow by 57.20% on average over the next years. This is a very strong growth
- Based on estimates for the next years, PRVA will show a quite strong growth in Revenue. The Revenue will grow by 10.44% on average per year.
EPS Next Y106.06%
EPS Next 2Y65.53%
EPS Next 3Y57.2%
EPS Next 5YN/A
Revenue Next Year16.36%
Revenue Next 2Y11.95%
Revenue Next 3Y12.41%
Revenue Next 5Y10.44%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. PRVA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 127.53, which means the current valuation is very expensive for PRVA.
- The rest of the industry has a similar Price/Earnings ratio as PRVA.
- Compared to an average S&P500 Price/Earnings ratio of 25.71, PRVA is valued quite expensively.
- Based on the Price/Forward Earnings ratio of 61.89, the valuation of PRVA can be described as expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of PRVA is on the same level as its industry peers.
- PRVA is valuated expensively when we compare the Price/Forward Earnings ratio to 23.83, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 127.53 | ||
| Fwd PE | 61.89 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PRVA is valued a bit more expensive than the industry average as 62.38% of the companies are valued more cheaply.
- 71.29% of the companies in the same industry are more expensive than PRVA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.41 | ||
| EV/EBITDA | 49.88 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- PRVA's earnings are expected to grow with 57.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.2
PEG (5Y)N/A
EPS Next 2Y65.53%
EPS Next 3Y57.2%
5. PRVA Dividend Analysis
5.1 Amount
- No dividends for PRVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PRVA Fundamentals: All Metrics, Ratios and Statistics
21.68
-0.05 (-0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-26 2026-02-26/bmo
Earnings (Next)05-06 2026-05-06/bmo
Inst Owners99.61%
Inst Owner Change0.49%
Ins Owners1.85%
Ins Owner Change7.46%
Market Cap2.68B
Revenue(TTM)2.12B
Net Income(TTM)22.92M
Analysts84.29
Price Target32.15 (48.29%)
Short Float %2.3%
Short Ratio3.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)43.55%
Min EPS beat(2)-8.97%
Max EPS beat(2)96.08%
EPS beat(4)1
Avg EPS beat(4)-2.92%
Min EPS beat(4)-60.96%
Max EPS beat(4)96.08%
EPS beat(8)1
Avg EPS beat(8)-23.29%
EPS beat(12)3
Avg EPS beat(12)-1.19%
EPS beat(16)6
Avg EPS beat(16)61.33%
Revenue beat(2)1
Avg Revenue beat(2)5.86%
Min Revenue beat(2)-6.18%
Max Revenue beat(2)17.91%
Revenue beat(4)3
Avg Revenue beat(4)4.55%
Min Revenue beat(4)-6.18%
Max Revenue beat(4)17.91%
Revenue beat(8)7
Avg Revenue beat(8)4.33%
Revenue beat(12)10
Avg Revenue beat(12)3.07%
Revenue beat(16)10
Avg Revenue beat(16)-7.25%
PT rev (1m)0%
PT rev (3m)0.39%
EPS NQ rev (1m)13.87%
EPS NQ rev (3m)9.04%
EPS NY rev (1m)8.83%
EPS NY rev (3m)8.58%
Revenue NQ rev (1m)-4.43%
Revenue NQ rev (3m)-29.88%
Revenue NY rev (1m)2.51%
Revenue NY rev (3m)-35.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 127.53 | ||
| Fwd PE | 61.89 | ||
| P/S | 1.26 | ||
| P/FCF | 16.41 | ||
| P/OCF | 16.41 | ||
| P/B | 3.64 | ||
| P/tB | 8.61 | ||
| EV/EBITDA | 49.88 |
EPS(TTM)0.17
EY0.78%
EPS(NY)0.35
Fwd EY1.62%
FCF(TTM)1.32
FCFY6.09%
OCF(TTM)1.32
OCFY6.09%
SpS17.16
BVpS5.96
TBVpS2.52
PEG (NY)1.2
PEG (5Y)N/A
Graham Number4.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.67% | ||
| ROE | 3.11% | ||
| ROCE | 4.27% | ||
| ROIC | 2.75% | ||
| ROICexc | 6.87% | ||
| ROICexgc | N/A | ||
| OM | 1.61% | ||
| PM (TTM) | 1.08% | ||
| GM | 9.87% | ||
| FCFM | 7.7% |
ROA(3y)1.75%
ROA(5y)-4.65%
ROE(3y)3.16%
ROE(5y)-7.26%
ROIC(3y)2.17%
ROIC(5y)N/A
ROICexc(3y)6.14%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)3.37%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-16.37%
OM growth 3YN/A
OM growth 5Y-12.3%
PM growth 3YN/A
PM growth 5Y-22.33%
GM growth 3Y-0.24%
GM growth 5Y-0.49%
F-Score6
Asset Turnover1.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 136.39 | ||
| Cash Conversion | 370.18% | ||
| Profit Quality | 712.96% | ||
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z | 4.32 |
F-Score6
WACC8.92%
ROIC/WACC0.31
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)607.4%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.55%
EPS 3Y9.35%
EPS 5Y-9.93%
EPS Q2Q%133.33%
EPS Next Y106.06%
EPS Next 2Y65.53%
EPS Next 3Y57.2%
EPS Next 5YN/A
Revenue 1Y (TTM)22.26%
Revenue growth 3Y16.09%
Revenue growth 5Y21.04%
Sales Q2Q%-31.71%
Revenue Next Year16.36%
Revenue Next 2Y11.95%
Revenue Next 3Y12.41%
Revenue Next 5Y10.44%
EBIT growth 1Y101.6%
EBIT growth 3YN/A
EBIT growth 5Y6.15%
EBIT Next Year470.08%
EBIT Next 3Y100.08%
EBIT Next 5Y56.77%
FCF growth 1Y49.53%
FCF growth 3Y51.38%
FCF growth 5Y33.52%
OCF growth 1Y49.53%
OCF growth 3Y51.28%
OCF growth 5Y33.26%
PRIVIA HEALTH GROUP INC / PRVA Fundamental Analysis FAQ
What is the fundamental rating for PRVA stock?
ChartMill assigns a fundamental rating of 5 / 10 to PRVA.
Can you provide the valuation status for PRIVIA HEALTH GROUP INC?
ChartMill assigns a valuation rating of 3 / 10 to PRIVIA HEALTH GROUP INC (PRVA). This can be considered as Overvalued.
Can you provide the profitability details for PRIVIA HEALTH GROUP INC?
PRIVIA HEALTH GROUP INC (PRVA) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for PRVA stock?
The Price/Earnings (PE) ratio for PRIVIA HEALTH GROUP INC (PRVA) is 127.53 and the Price/Book (PB) ratio is 3.64.
Can you provide the financial health for PRVA stock?
The financial health rating of PRIVIA HEALTH GROUP INC (PRVA) is 7 / 10.